Because undesired activation by autoantibodies contributes to the pathogenesis of various chronic inflammatory disorders, targeting of FcγR-TLR signaling may be a valuable tool to suppress inflammation in diseases such as RA, systemic lupus erythematous (SLE), and inflammatory bowel disease (IBD). Here, FCGR2A is linked to systemic lupus erythematosus.